You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5413 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
High Cost Therapy Funding Program
    Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
ODB - General Benefit
    dexamethasone
Aug 2025
Drug
Other Name(s): Epkinly™
Updated
Aug 2025
Drug
Other Name(s): Kimmtrak®
Updated
Aug 2025
Drug
Other Name(s): Camptosar®
Updated
Aug 2025
Drug
Other Name(s): Neulasta®, Lapelga®, Fulphila™; Ziextenzo®; Nyvepria™, Niopeg®, Pexegra™
Updated
Aug 2025
Drug
Other Name(s): Femara®
Updated
Aug 2025
Drug
Other Name(s): Scemblix™
Updated
Aug 2025
Drug
Other Name(s): Tykerb®
Updated
Aug 2025
Drug
Other Name(s): Caelyx®
Updated
Aug 2025

Pages